Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $0.0091
Latest analyst grade actions
1175 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-20
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 40.05 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 23.03 | Oscillator | Neutral |
| Williams %R (14) | -100.00 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.00 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 20.48 (+DI 25.3 / -DI 51.2) | Trend | Sell |
| EMA 20 | 0.01 | MA | Strong Sell |
| SMA 20 | 0.01 | MA | Strong Sell |
| EMA 50 | 0.01 | MA | Strong Sell |
| SMA 50 | 0.01 | MA | Strong Sell |
| SMA 200 | 0.01 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
TORONTO, ON / ACCESS Newswire / August 26, 2026 / Blueberries Medical Corp. (CSE:BBM)(OTCID:BBRRF)(FRA:1OA) (the "Company" or "Blueberries"), a consumer science company focused on health, wellness and longevity, and a licensed producer of both psychoactive and non-psychoactive cannabis derivatives in Colombia, announces a non-brokered private placement consisting of the sale of 84,615,385 common shares ("Common Shares") at a price of C$0.013 per Common Share for aggregate gross proceeds of approximately C$1,100,000 (or approximately US$781,000) (the "Offering"). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes.
TORONTO, ON / ACCESS Newswire / July 29, 2026 / Blueberries Medical Corp. (CSE:BBM)(OTCID:BBRRF)(FRA:1OA) (the "Company" or "Blueberries"), a consumer science company focused on health, wellness and longevity, and a licensed producer of both psychoactive and non-psychoactive cannabis derivatives in Colombia, is pleased to announce a non-brokered private placement consisting of the sale of 84,615,385 common shares ("Common Shares") at a price of C$0.013 per Common Share for aggregate gross proceeds of approximately C$1.1 million (or approximately US$781,000) (the "Offering"). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 31, 2026 | — | -0.00 | — | $24.71K |
| May 28, 2026 | — | -0.00 | — | $30.72K |
| Nov 24, 2025 | — | -0.00 | — | $35.61K |
| Sep 1, 2025 | — | -0.00 | — | $57.87K |
| May 28, 2025 | — | -0.00 | — | $55.22K |
| Nov 25, 2024 | — | -0.00 | — | $60.97K |
TTM vs. 5-year historical average (annual ratios)
| Metric | BBRRF | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -4.8x | -3.4x · sector 20.7x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 172.8x | 8.5x | Elevated |
| Price / Sales | 17.8x | 28.6x | Discount |
| EV / EBITDA | -7.1x | -5.6x | Elevated |
| Return on equity | -332.6% | — | Weak |
| Gross margin | 36.9% | -20.9% | Below hist. |
| Debt / Equity | 0.29 | 0.47 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -55.88 | Distress |
Discounted cash flow model